Quigley Corporation's (QGLY) QR-435 Test Compound 100% Effective In Animal Prophylaxis Experiment 
10/19/2005 5:10:17 PM

Outperforms a Leading Prescription Influenza Drug In Independent Virology Study

DOYLESTOWN, PA.--(BUSINESS WIRE)--Nov. 6, 2003--The Quigley Corporation (Nasdaq: QGLY - News) today announced that an independent study by Retroscreen Virology Ltd, found that intranasal application by spray of Quigley Pharma's QR-435 was 100 percent effective in preventing non-infected ferrets in close proximity to an infected ferret from becoming infected with the influenza A virus (the "prophylaxis experiment").

The study also found that intranasal application by spray of QR-435 could prevent an infected animal, when treated, from transmitting the influenza A virus to other animals in close proximity (the "transmission experiment"). The ferret is an established animal model for the study of influenza infection. On the strength of these data, Quigley intends to initiate a Phase II proof of concept human trial in Europe.

The study examined a total of 50 ferrets. The study determined that the QR-435 test compound was 100 percent effective at preventing infection in the recipient animals in the prophylaxis experiment, and was partially effective in the transmission experiment.

In the prophylaxis experiment, a fourfold rise in antibodies against the influenza A virus, or seroconversion, was used to determine Influenza infection. The recipient animals receiving QR-435 outperformed a leading prescription Influenza drug (comparison drug) and the placebo treatment groups. 100 percent of animals in both the (comparison drug) treatment group (eight of eight) and placebo treatment group (two of two) seroconverted. By contrast, none of the animals (zero of eight) in the QR-435 treatment group seroconverted.

In the transmission experiment, 100 percent of animals in both the placebo treatment group (four of four) and the (Comparison Drug) treatment group (eight of eight) seroconverted. By comparison, only 57 percent (four of seven) of those animals tested in the QR-435 treatment group seroconverted. Seroconversion was defined as a four-fold rise in antibodies against the influenza A virus.

Dr. Richard Rosenbloom, Executive Vice President and Chief Operations Officer of Quigley Pharma Inc., stated, "These results are exciting and provide ample encouragement to proceed to the next level of development with a goal of prescription drug approval."

Retroscreen Virology Ltd, an independent research virology company affiliated with the University of London, conducted the study. Professor John S. Oxford, the firm's senior scientist, is Professor of Virology at St. Bartholomew's and The Royal London School of Medicine and Dentistry at the University of London. He is the co-author of two standard texts on influenza and virology, and has published 250 scientific papers throughout the world.

Retroscreen specializes in developing anti-viral compounds and vaccines, and has worked with many pharmaceutical companies to assist them in developing products that now help to fight viral disease worldwide. Additional information is available on the company's website at

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the QR formulation to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

The Quigley Corporation (Nasdaq: QGLY, is a leading developer and marketer of diversified health products including the Cold-EezeĀ® family of patented zinc gluconate glycine (ZIGG(TM)) lozenges and sugar free tablets. Cold-Eeze is the only (ZIGG(TM)) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the company has formed Quigley Pharma Inc. (, a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally-derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition


Lippert Heilshorn & Associates David K. Waldman / John W. Heilshorn, 212-838-3777 or

The Quigley Corporation Carl Fonash, 267-880-1111

Source: The Quigley Corporation